Humans have 48 distinct ABC transporters that belong to seven subfamilies (A-G) and differ in size, architecture, and domain arrangement 1,2 . ABCG2, also known as breast cancer resistance protein (BCRP), is a multidrug transporter that has physiological roles in many tissues including the mammary gland and the blood-brain, bloodtestis, and maternal-fetal barriers [3][4][5][6] . ABCG2 has a minor role in uric acid transport, but its dysfunction is associated with several disease states linked to hyperuricaemia including gout, kidney disease, and hypertension
. ABCG2, also known as breast cancer resistance protein (BCRP), is a multidrug transporter that has physiological roles in many tissues including the mammary gland and the blood-brain, bloodtestis, and maternal-fetal barriers [3] [4] [5] [6] . ABCG2 has a minor role in uric acid transport, but its dysfunction is associated with several disease states linked to hyperuricaemia including gout, kidney disease, and hypertension 7 . Studies with ABCG2 knockout mice have revealed the effect of the protein on the oral availability of drugs in the gastrointes tinal tract, whereas ABCG2 expressed in the canalicular membrane and in the apical membrane of kidney cells secretes diverse compounds into bile or urine. These two effects emphasize the impact of ABCG2 func tion on the pharmacokinetics of commonly used drugs. Consequently, ABCG2 is on the US Food and Drug Administration and the European Medicines Agency lists of transporters to be checked for drug-drug interactions 8 . Like its functional homologues ABCB1 and ABCC1, ABCG2 also has a notorious function in extruding antitumour drugs from a variety of cancer cells, which can result in multidrug resistance, a serious obstacle in cancer treatment [9] [10] [11] [12] . While its remarkable substrate polyspecificity and widespread localization make it a contributor to multidrug resistance, it has so far failed to emerge as a viable therapeutic target and thus an understanding of its drugbinding pocket is of paramount importance 6, 7, [13] [14] [15] . ABCG2 was also considered a marker for haematopoietic stem cells, and an inhibitory conformational anti body (5D3) against the human protein was developed 16 . Over recent decades, in vivo studies have provided detailed insight into the localization, physiological functions, trafficking, substrate specificity, and single nucleotide polymorphisms of ABCG2 (refs 15-17) . However, our mechanistic understanding of ABCG2 is limited because no highresolution structure is available, which is partly because of the challenges associated with its overexpression and functional purification. Whereas a crystal structure of the human sterol transporter ABCG5/G8 was recently reported 18 , direct structural insight into ABCG2 was limited to lowresolution electron microscopy imaging 19 and an in silico model based on the structure of ABCG5/G8 (ref. 20) . In this study, we used singleparticle cryoelectron microscopy (cryoEM) to determine the structure of wildtype, human ABCG2 in complex with two antigenbinding fragments of 5D3 (5D3Fab).
In vitro function and structure determination
ABCG2 was expressed in human embryonic kidney cells (HEK293), purified in detergent solution, and reconstituted both into prote oliposomes and into lipidic nanodiscs for functional studies. The reconstituted protein catalysed transport of estrone3sulfate (E 1 S), a bona fide substrate of ABCG2, into proteoliposomes, with Michaelis constant (K m ) values comparable to those previously reported using membrane vesicles derived from insect or human cells 21, 22 (Fig. 1a , b and Extended Data Fig. 1 ). E 1 S transport was inhibited by 5D3Fab, but only if the antibody fragments were present in the lumen (inside) of the proteoliposomes. Thus our in vitro assays are consistent with earlier conclusions that 5D3 bound the extracellular surface of ABCG2 (ref. 16 ). Transport of E 1 S was completely abolished by the synthetic inhibitor Ko143 (Fig. 1b and Extended Data Fig. 1 ) 23 . Both 5D3Fab and Ko143 reduced the ATPase activity of ABCG2 in liposomes while a mutation of the WalkerB residue Glu211 to a glutamine (E211Q) abolished activity (Fig. 1c) .
Because nanodiscs contain a patch of lipid bilayer, they represent a physiologically relevant environment for structural studies of membrane proteins 24, 25 . Negativestain EM revealed that two 5D3Fab fragments bound to a single, nanodiscreconstituted ABCG2 homodimer. The resulting ABCG2-5D3(Fab) complex had a molecular mass of ~ 250 kDa and maintained twofold symmetry. Singleparticle cryoEM analysis resulted in a threedimensional reconstruction at an overall resolution of 3.8 Å (Fourier shell correlation (FSC) = 0.143 criterion; Extended Data Fig. 2 ). The transmembrane domains (TMDs) and the variable domains of 5D3Fab were better resolved, with local resolu tions approaching ~ 3 Å (Extended Data Fig. 3 ). The quality of the EM density map allowed de novo building of an atomic model of the TMDs and of the variable domain part of 5D3Fab (Extended Data Fig. 4) . We independently determined the Xray structure of 5D3Fab at 1.5 Å resolution (Extended Data Fig. 5 ), which provided an initial model ABCG2 is a constitutively expressed ATP-binding cassette (ABC) transporter that protects many tissues against xenobiotic molecules. Its activity affects the pharmacokinetics of commonly used drugs and limits the delivery of therapeutics into tumour cells, thus contributing to multidrug resistance. Here we present the structure of human ABCG2 determined by cryo-electron microscopy, providing the first high-resolution insight into a human multidrug transporter. We visualize ABCG2 in complex with two antigen-binding fragments of the human-specific, inhibitory antibody 5D3 that recognizes extracellular loops of the transporter. We observe two cholesterol molecules bound in the multidrug-binding pocket that is located in a central, hydrophobic, inward-facing translocation pathway between the transmembrane domains. Combined with functional in vitro analyses, our results suggest a multidrug recognition and transport mechanism of ABCG2, rationalize disease-causing single nucleotide polymorphisms and the allosteric inhibition by the 5D3 antibody, and provide the structural basis of cholesterol recognition by other G-subfamily ABC transporters.
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to be docked into the EM density map. In contrast, the nucleotide binding domains (NBDs) of ABCG2 were resolved at lower resolution, most probably because of their inherent flexibility and a lack of particle sideviews in the EM data. We therefore generated a homology model of the ABCG2 NBD based on the recent structure of ABCG5/G8 (ref. 18) and docked this into our EM density map, where modifications to secondary structure elements could be fitted.
Architecture of ABCG2
Like other Gsubfamily ABC transporters, ABCG2 is a 'half transporter' with one NBD and one TMD fused to a single polypeptide chain. The functional form of ABCG2 is a homodimer with a molecular mass of ~ 144 kDa. In the ABCG2-5D3(Fab) complex, the Fab frag ments bind at an ~ 35° angle relative to the membrane plane (Fig. 2a) . The fold of ABCG2 (Fig. 2b, c) is similar to that of ABCG5/G8, but distinct from that found in the Bsubfamily of ABC transporters, exem plified by the bacterial multidrug transporter homologue Sav1866 (ref. 26) or the mouse ABCB1 (Pglycoprotein) 27, 28 . The transmem brane helices and intracellular loops of ABCG2 are shorter than Bsubfamily ABC transporters, resulting in a smaller distance between the NBDs and the membrane, thus resembling the more compact bacterial ABC importers 29, 30 . The TMD interface is formed by TM2 and TM5a of opposing ABCG2 monomers. The two 406GXXXG410 motifs, previously postulated to be involved in dimerization 31 , are located on opposite sides of the transporter (Fig. 2b) and do not con tact each other. While the architecture of ABCG2 is similar to that of ABCG5/G8 (Extended Data Fig. 6b ), there are important differences that could not be predicted by the in silico model of ABCG2 (ref. 20) owing to model bias (rootmeansquare deviation between TMDs of our structure and the in silico model is 2.2 Å) First, there is a backbone shift in TM2 and TM5a of both monomers. This causes ABCG2 to form an inward facing cavity (see below), a feature that is not present in ABCG5/G8. Second, the structure of the external loop EL3 is distinct in the two structures.
Notably, the NBDs of ABCG2 remain in contact despite the absence of bound nucleotide. This was also observed in the structure of ABCG5/ G8 but differs from the large conformational flexibility reported for Bsubfamily ABC transporters [32] [33] [34] . The NBD of each ABCG2 monomer is linked to TM1a (known in ABCG5/G8 as connecting helix (CnH)) via a highly charged linker. This linker is not visible in the ABCG5/G8 Xray structure or in the ABCG2 EM density, most probably because of its flexibility; therefore, it has not been modelled. The C2 motif of ABCG2, previously proposed to be important for ATP binding 35 , is located on an α helix at the bottom of the NBDs, ~20 Å away from the WalkerA motif and ~45 Å from the signature motif, precluding its direct involvement in ATP binding to the canonical site (Fig. 2b) .
Interaction of inhibitory 5D3 antibody with ABCG2
Each 5D3Fab interacts with extracellular loops of both ABCG2 monomers (Fig. 3a) . Most contacts are formed by EL3, the longest of the extracellular loops in ABCG2, connecting TM5c and TM6a. EL3 contains three cysteines (C592, C603, C608) and a single Nglycosylation site (N596; Fig. 3b ). Our map showed clear density for up to two GlcNAc residues attached to N596, and there is equally clear density for two intramolecular disulfides (C592-C608 and C592′ -C608′ ) as well as one intermolecular disulfide, C603-C603′, which is positioned on the twofold symmetry axis of the ABCG2 homodimer. The proper formation of the intermolecular disulfide in our overexpression system was validated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), where fully dimeric ABCG2 was observed in nonreducing conditions both in the presence and absence of 5D3Fab ( Fig. 3c and Extended Data Fig. 7a ). The intramolecular disulfides stabilize the structure of EL3, which is in line with previous reports that C592 and C608 are important for ABCG2 maturation and activity 36, 37 . In contrast, the intermolecular disulfide did not seem to be critical for transport function in cellular assays, as mutation to various residues abolished the formation of the covalent dimer, but did not interfere with drug extrusion 38 . Nglycosylation at N596 has been found to be essential for ABCG2 maturation, and mutations of this residue have resulted in protein destabilization and enhanced ubiquitinmediated degradation 39 . N596 is not part of the ABCG2-5D3(Fab) interface, explaining why Nglycosylation of ABCG2 does not affect the binding of 5D3 (Fig. 3b ) 40 . The physiological relevance of the interface observed in our structure is supported by the finding that 5D3Fab is selective for human ABCG2 and does not bind to purified rat ABCG2 (Extended Data Fig. 7b ). This can be rationalized by differences in the EL3 sequences of rat and human ABCG2, in particular those residues involved in the interface with 5D3 (N600, N601, and N604) (Fig. 3e) . In addition, rat ABCG2 contains a second Nglycosylation site (N600), which probably interferes with 5D3 binding.
The binding of two 5D3Fab fragments is consistent with the two fold symmetry of the ABCG2 homodimer. In contrast, only one Fab fragment of the inhibitory antibody UIC2 bound to the multidrug transporter ABCB1, which is asymmetric 32 . We investigated whether two copies of 5D3Fab are required for inhibition. Using nanodisc reconstituted ABCG2, we found that only one 5D3Fab per ABCG2 homodimer is required to observe maximal inhibition of the ATPase activity (Fig. 3d) . This suggests that a single 5D3 molecule can inhibit transport activity of ABCG2 by clamping the ABCG2 monomers 
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together, precluding the formation of an outwardfacing conforma tion that is essential for active transport. In addition, the inhibition of ATPase activity suggests relatively strict conformational coupling of the TMD and NBD motions, given that the antibodybinding site and the ATPase sites are some ~ 80 Å apart and on opposite sides of the membrane. It was previously shown that, whereas AMP, ADP, and ATP did not appear to affect 5D3 binding in vitro, binding of 5D3 was reduced by the presence of AMPPNP (adenosine 5′ (β γ imido) triphosphate) or orthovanadate 40 .
Translocation pathway and substrate-binding site
ABCG2 can bind or transport structurally diverse molecules ranging from hematoporphyrin, mitoxantrone, and methotrexate to inhibitors such as the tyrosine kinase inhibitor gefitinib or the fumitremorgin Cderived molecule Ko143 (ref. 23). The structure of ABCG2-5D3(Fab) revealed an inwardopen conformation with a deep, slitlike cavity that is primarily lined by TM2 and TM5a from the two ABCG2 monomers. This cavity (cavity 1) opens to the cytoplasm and to the inner leaflet of the lipid bilayer, and it reaches more than halfway across the membrane to residues L554 and L554′ of opposing ABCG2 monomers. These leucine residues form a plug that separates cavity 1 from a secondary, smaller cavity (cavity 2) located below the EL3 external loops (Fig. 4a) . Cavity 2 is inaccessible in the present confor mation and is likely to have a lower affinity for substrate owing to its less pronounced hydrophobic surface, which may help promote substrate release to the extracellular side during the transport cycle.
Given the size, hydrophobic nature, and accessibility of cavity 1 to the cytoplasm and the membrane, we assign it the role of a multidrug binding pocket. Its geometry makes it suitable to accommodate flat, polycyclic and hydrophobic substrates (Fig. 4b) . We observed two large density features that were symmetrically located in cavity 1. Their size and shape were inconsistent with bound phospholipids and suggested a polycyclic molecule (Fig. 4c, d ). Only three such molecules were present during ABCG2 reconstitution into nanodiscs: cholesterol, cholesteryl hemisuccinate, and cholate. Of these, hemisuccinate could be excluded as a candidate because its substituents would cause a steric clash with the L554 plug at the top of cavity 1. While cholate, used for the preparation of nanodiscs, would fit the density, functional data suggest that ABCG2 is not responsive to cholate in the presence or absence of E 1 S (Extended Data Fig. 1f ). We therefore interpreted the density features as two cholesterol molecules that are in contact with six hydrophobic residues from each ABCG2 monomer (F432 and F439 from TM2 and L539, I543, V546, and M549 from TM5a). The shape of the density guided us to fit the cholesterols with their hydroxyl groups pointing into the cavity, as the opposite orientation would generate a steric clash with the L554 plug (Extended Data Fig. 4e ). We conclude that cholesterol, which is not a bona fide substrate, can nevertheless bind to ABCG2 and reveals where the chemically similar, physiological substrate E 1 S would bind. Two E 1 S molecules could indeed be fitted in the substratebinding pocket where the cholesterol molecules are bound, with their sulfate groups pointing towards the cytoplasm. The conclusion that cavity 1 represents an ABCG2 substratebinding site is supported by the observation that the basal ATP hydrolysis rate of cholesterolbound, nanodiscreconstituted ABCG2 is indistinguishable from the E 1 Sstimulated ATPase activity in liposomes (Extended Data  Fig. 1f) .
While ABCG2 does not catalyse significant cholesterol transport in vivo, its function was previously shown to be regulated by cholesterol 41 . In contrast, the other members of the ABCG subfamily (ABCG1 (ref. 42) , ABCG4 (ref. 43) , and ABCG5/G8) are reported sterol trans porters. The residues in contact with bound cholesterol in ABCG2 are either fully conserved or substituted by other hydrophobic residues in the other Gsubfamily ABC transporters, with the exception of V546, which corresponds to N568 in ABCG8 (Fig. 4e, f) . Intriguingly, two of these six residues have been investigated in human ABCG5/G8. A mutation of Y432 in ABCG5 (corresponding to F439 in ABCG2) to an alanine disrupted in vivo cholesterol transport 18 . Our struc ture reveals that F439 forms a stacking interaction with the Bring of bound cholesterol (Fig. 4d) . In addition, a mutation of A540 in ABCG5 (corresponding to V546 in ABCG2) to a phenylalanine also interfered with biliary cholesterol transport, which was interpreted as a possible steric clash with bound cholesterol by the larger, aromatic residue 18 . These results are fully in line with our structural data and validate our identification of a conserved sterolbinding cavity that is probably shared by other Gsubfamily ABC transporters, even though the orientation of cholesterol may be different when recruited from the lipid bilayer (hydroxyl group pointing to the cytoplasm).
Cavity 2 observed in ABCG2 is not present in the ABCG5/G8 structure owing to differences in the structure of EL3. The sequence similarity in EL3 is low among ABCG subfamily members (Extended monomer is coloured as a rainbow spectrum ranging from blue to red. c, Topology of the ABCG2 TMD coloured as in b. Cysteines forming inter and intramolecular disulfide bonds (C592, C603, and C608) are indicated, as is the Nglycosylated residue N596.
Article reSeArcH Data Fig. 6c ). Whereas ABCG1, ABCG4, and ABCG5 each have two cysteines in similar positions to ABCG2 (C587, C600), ABCG8 has no cysteines in EL3. It is conceivable that the formation of intramolecular disulfides in EL3 of ABCG2 contributes to its function as a multidrug transporter, because EL3 is a key element in forming cavity 2.
Single nucleotide polymorphisms of ABCG2
The mutation Q141K is an ABCG2 single nucleotide polymorphism that is linked to hyperuricaemia and gout 44 . It results in decreased ABCG2 expression, misfolding, and degradation by the endoplasmic reticulumassociated protein degradation (ERAD) system. Nevertheless, residual ABCG2 (Q141K) in the plasma membrane shows transport activity 45 . Despite the lower resolution in the NBDs of our ABCG2 structure, we can place Q141 on the α helix adjacent to TM1a (Fig. 2b) . TM1a is an amphipathic α helix, and its positively charged side faces Q141. We expect that the mutation of Q141 to a positively charged lysine would result in electrostatic repulsion that could distort TM1a, affecting ABCG2 folding. Another single nucleotide polymorphismassociated residue, R482, has been exten sively studied and reported to be important for ABCG2 function. Its mutation to various residues affects substrate specificity 46 , although it was proposed that this is not through direct substrate interaction 47 . In our structure, R482 is located on TM3 (Fig. 2b) where it forms a stabilizing hydrogen bond with S521 on TM4, but is approximately 9 Å away from the substratebinding pocket. The reported impact on substrate specificity is therefore probably caused by allosteric effects.
Proposed transport mechanism
Our results allow us to formulate a transport and inhibition mecha nism that is consistent with the available biochemical and functional data. The mechanism invokes ATPdriven alternating access 48 , whereby the closing of the NBD interface in response to ATP binding converts the substratebound, inwardopen conformation of ABCG2 to an outwardfacing state that can release the substrate to the outside (Fig. 5) . In the absence of bound ATP, the hydrophobic substratebinding site (cavity 1) is exposed to the cytoplasm and the inner leaflet of the plasma membrane, from where substrate is recruited. In this state, cavity 2 is empty but occluded. Upon binding of substrate and ATP, confor mational changes convert the transporter to an outward facing state, where the substrate is moved into cavity 2, from where it is expelled into Article reSeArcH the extracellular medium by means of a hydrophobic mismatch. The transporter cannot convert to an inwardfacing state if the substrate is present in cavity 2, owing to steric clashes. Thus, ATP hydrolysis and the conversion to an inwardfacing state are directly linked to substrate release, providing the molecular basis of active transport. The inwardfacing state can be inhibited by 5D3Fab. Although two 5D3Fab fragments can bind to the extracellular side, only one is required to clamp the ABCG2 monomers together, restricting their relative motion and allosterically impairing both substrate transport and ATP hydrolysis by shifting the equilibrium to the inwardfacing conformation. This demonstrates strong coupling between TMDs and NBDs in ABCG2, which in turn can provide a molecular expla nation for substrateinduced ATPase stimulation: substrate binding to cavity 1 probably stimulates the ATPase activity of the transporter by stabilizing the TMD interface, which results in closer proximity of the NBDs. The structure presented here reveals that inhibitory 5D3Fab and substrate binding are not mutually exclusive, but transport from this state is impossible if the TMDs are externally clamped together by the antibody fragments.
Conclusions
The ABCG2 structure represents the first, to our knowledge, high resolution structure of a human multidrug ABC transporter. The observed geometry and architecture of the hydrophobic substrate binding cavity provide the structural basis of the polyspecific interac tion with diverse hydrophobic compounds and offer an opportunity to model drugs and inhibitors into the multidrugbinding pocket, which may facilitate structurebased drug and inhibitor design. Our results also define the mechanism by which an inhibitory antibody, through longrange allosteric effects, precludes conformational changes that are essential for substrate transport. While probing of additional drug and inhibitorbound states is essential for a complete mechanistic under standing, our results can already be used for diagnostic and potential therapeutic approaches.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Figure 5 | Proposed transport mechanism. ABCG2 monomers are coloured red and blue, with cysteines forming disulfide bonds (yellow dashed lines) labelled 's' . ATPdriven transport of substrate (orange hexagon labelled 'S') occurs between states 1 and 2 (states indicated by circled numbers). Substrate enters cavity 1 (labelled '1') from the cytoplasm or from the inner leaflet of the membrane, but cannot access cavity 2 (labelled '2') owing to the leucine plug (shown between ABCG2 monomers in states 1 and 3). Closing of the NBD interface converts state 1 to an outwardfacing state 2 that can release substrate to the outside.
The release of inorganic phosphate (P i ) is accompanied by the conversion of ABCG2 from state 2 to state 1. In state 3 (which corresponds to the structure presented here), two 5D3Fab fragments (shaded green and yellow and labelled Fab) bind to the extracellular side of ABCG2. This leads to inhibition of transport and ATPase activity (indicated by red arrows to the left). While inhibition of transport occurs by clamping the ABCG2 monomers together, inhibiting ATP hydrolysis occurs allosterically (depicted by dashed red arrows).
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MethOds
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Expression and purification of human ABCG2. Human fulllength ABCG2 (Uniprot: Q9UNQ0), containing an amino (N)terminal Flag tag, was expressed in HEK293EBNA (Thermo Fisher Scientific) cells as previously described 49 . The cells were treated with 5 μ M kifunensine (Toronto Research Chemicals) for 30 min before transfection. After transfection, the cells were incubated for 2 days at 37 °C before harvesting.
Transfected cells were solubilized in 40 mM HEPES buffer pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 1 mM PMSF (phenylmethylsulfonyl fluoride), 2 μ g ml −1 DNaseI (Roche), and protease inhibitor cocktail (Sigma) with 1% DDM (ndodecylβ dmaltopyranoside) + 0.1% CHS (cholesteryl hemisuccinate) (w/v) (Anatrace) for 90 min at 4 °C. The solubilized lysate was ultracentrifuged at 100,000g and the supernatant was incubated with antiFlag M2 affinity agarose gel (Sigma). The gel was washed extensively with purification buffer containing 40 mM HEPES pH 7.5, 150 mM NaCl, and 0.026% DDM + 0.0026% CHS (w/v). ABCG2 was eluted with Flag peptide (Sigma) and treated with EndoF before being loaded into a TSKgel G3000SWXL column (Tosoh Bioscience). The peak fractions were collected and reconstituted into nanodiscs or liposomes and used for either cryoEM studies or functional assays. ABCG2-liposome preparation for transport and ATPase assays. A brain polar lipid:cholesterol (BPL:chol) (Avanti Polar Lipids) mixture was prepared at a 4:1 (w/w) ratio as described previously 50 . Briefly, the BPL:chol mixture was extruded 11 times through a 400 nm filter and destabilized with 0.17% (v/v) Triton X100. Detergentpurified ABCG2 was then mixed with BPL:chol at a 100:1 (w/w) lipid:protein ratio. Detergent was removed with BioBeads and proteoliposomes were spun at 100,000g, resuspended in 25 mM HEPES pH 7.5, 150 mM NaCl at a final lipid concentration of 10 mg ml
, and the reconstitution efficiency was determined 51 . ABCG2-nanodisc preparation for ATPase assays. Membrane scaffold protein (MSP) 1D1 was expressed and purified as described previously 24 . BPL:CHS (4:1) (w/w) was solubilized with a 3× molar excess of sodium cholate using a sonic bath. Solubilized BPL:CHS was mixed with MSP 1D1 and detergentpurified ABCG2 at a molar ratio of 100:5:0.2 (lipid:MSP:ABCG2). BioBeads were added and the sample was incubated at 4 °C overnight. BioBeads were removed and the sample was spun at 100,000g before being loaded into a Superdex 200 10/300 column (GE Healthcare) and used either for cryoEM studies or ATPase assays. Transport assays and E 1 S K m determination. Liposomereconstituted ABCG2 was freezethawed in the presence or absence of a 3× molar excess of 5D3Fab to get the 5D3Fab inside the proteoliposomes. Freeze thawing was not detrimental to the function of ABCG2. Proteoliposomes were then extruded through a 400 nm polycarbonate filter and diluted to 4 mg ml −1 lipid in transport buffer (25 mM HEPES pH 7.5, 150 mM NaCl). MgCl 2 (5 mM) and 3 HE 1 S (1-50 μ M) were added in the presence or absence of 5D3Fab or Ko143 and the samples incubated for 5 min at 30 °C. The transport reaction was initiated by the addition of 2 mM ATP. To stop the reaction, samples were removed, added to icecold transport buffer containing unlabelled E 1 S, filtered using a Multiscreen vacuum manifold (MSFBN6B filter plate, Millipore) and washed three times. Radioactivity trapped on the filters was measured using a Perkin Elmer 2450 Microbeta2 microplate scintillation counter. Data were analysed and curves were plotted using the nonlinear regression Michaelis-Menten analysis tool and initial rates were deter mined using linear regression in GraphPad Prism 7 (GraphPad Software, La Jolla, California, USA). ATPase assays and stoichiometry. ATP hydrolysis activity was assessed as described previously 52 . All reactions were performed at 37 °C in the presence of 2 mM ATP and 10 mM MgCl 2 . E 1 S (50 μ M), 100 μ M sodium cholate, saturating amounts of Ko143, and a 3× molar excess of 5D3Fab were used to assess their stimulating or inhibitory effects. The molar ratios of nanodiscreconstituted ABCG2 and 5D3Fab were varied to determine the functional stoichiometry. For ATPase assays in proteoliposomes, samples were freezethawed and extruded as described above. ATPase rates were determined using linear regression in GraphPad Prism 7. Cryo-EM data acquisition. CryoEM grids of nanodiscreconstituted ABCG2-5D3(Fab) were prepared using a Vitrobot Mark IV (FEI) with the environmental chamber set at 95% humidity and 10 °C. Aliquots (3 μ l) of the complex, at a concentration of ~ 0.2 mg ml −1 , were placed on glowdischarged Quantifoil car bon grids (300 mesh, copper). Grids were blotted for 1.5 s and flashfrozen in a mixture of liquid ethane and propane cooled by liquid nitrogen. Grids were imaged with a Titan Krios (FEI) electron microscope that operated at 300 keV equipped with a QuantumLS energy filter and a K2 Summit electron counting direct detec tion camera (Gatan). Images were recorded using SerialEM 53 in superresolution mode using a 20 eV slit width of the GIF energy filter at a nominal magnifica tion of 130,000× , resulting in a calibrated superresolution pixel size of 0.5196 Å (physical pixel size 1.039 Å). Defocus was set to vary from − 1.5 to − 2 μ m. The super resolution micrographs were downsampled twice by Fouriercropping and driftcorrected and doseweighted using MotionCor2 (ref. 54) through the Focus suite 55 . Each image was dosefractionated to 40 frames (16 s exposure in total, 0.4 s per frame). The dose rate was set to ~ 4.5 electrons per pixel per second (~ 1.7 electrons per square ångström per frame), leading to a total dose of ~ 67 electrons per square ångström (Extended Data Table 1 ). Focus was used to remove bad micrographs manually from the data set. Image processing. The driftcorrected, doseweighted micrographs were imported in RELION2.02beta [56] [57] [58] , which was used for all data processing except where specified. Contrast transfer function (CTF) parameters were estimated with GCTF 59 . Micrographs had a calculated defocus of − 1.1 to − 2.5 μ m. Particles were picked in templatefree manner using Gautomatch 60 . A total of 92,326 particles were selected from 1,702 electron micrographs. After three rounds of two dimensional classification and selection of particles belonging to 'good' classes, the data set was reduced to 32,806 particles. These particles were used to generate a model with threedimensional autorefine. The resolution of this initial map was 5.9 Å. This map was then filtered to 20 Å and projected in evenly spaced (15°) directions. Using these projections as templates, a total of 232,608 particles could be picked from the data set. After three steps of twodimensional classification and selection, we obtained a final data set of 97,612 particles. Refinement of these particles against the same starting model as before using the threedimensional autorefine procedure resulted in a 4.2 Å map. After postprocessing (including soft masking and Bfactor sharpening with the automatically determined Bfactor of − 142.3 Å 2 ) in RELION1.4 (refs 56, 57), a map with a resolution of 3.8 Å (by FSC using the 0.143 Å cutoff criterion [61] [62] [63] ) was obtained. To assist modelling, a localresolutionfiltered map was calculated with RELION2.02beta (using a Bfactor of 142.3 Å 2 ).
Model building and refinement. For model building, we used mainly the postprocessed map, but also the localresolutionfiltered map and the original refinement map. The Coot program 64 was used for all modelling steps. 5D3Fab was placed as a rigid body followed by separate fitting of the variable domain and constant domain. A halftransporter atomic model for ABCG2 was generated using the HHpred server with MODELLER 65 , utilizing the ABCG5 Xray structure 18 (chain A of Protein Data Bank (PDB) accession number 5DO7). The TMD and NBD domains were fitted separately in the electrostatic potential map. The halftransporter atomic coordinates were then duplicated and rigidbody docked into the region of the map corresponding to the other half of ABCG2 to complete the full transporter model.
The postprocessed map was of excellent quality and allowed de novo model building (Extended Data Fig. 4 ) of the ABCG2 TMD and the variable domain of the 5D3Fab. For the constant domain of 5D3Fab, we were especially careful when adapting the model to the map and took advantage of the localresolution filtered map. In the region of the ABCG2 NBDs, the postprocessed map was of lower quality than in the regions of ABCG2 TMD and 5D3Fab. A similar reduced resolution of NBDs was recently observed in the cryoEM structures of the zebra fish CFTR protein and human TAP 66, 67 . Given the lower resolution of the density covering the NBDs, we generated an NBD model based on the crystal structure of ABCG5/G8, which shares ~ 40% sequence identity in the NBD region. Upon docking this model into the density, we could adjust the position of the secondary structure elements by fitting them into the density. We used the local resolution filtered map and the original nonpostprocessed map for very conservative adjustment of the model, guided by the structures of ABCG5 and ABCG8 (chains A and B, respectively, of PDB accession number 5DO7), the HHpred models using these structures as a template, as well as HHpred models based on the structures of Thermotoga maritima TM_0544 (PDB accession number 1VPL), Alicyclobacillus acidocaldarius CysA 68 (chain A of PDB accession number 1Z47), T. maritima TM_1403 (chain A of PDB accession number 4YER), Geobacillus stearothermophilus ArtP in complex with ADP/Mg 2+ (chain A of PDB accession number 2OLJ), and Thermoanaerobacter tengcongensis CbiO 69 (chain B of PDB accession number 4MKI). We then placed two cholesterol molecules in cavity 1 of the ABCG2 TMD in the orientation that resulted in the best visual fit to the map. Finally, the complete ABCG2-5D3(Fab) atomic model was refined against the localresolutionfiltered map (using a resolution limit of 3.8 Å) with phenix. real_space_refine 70 . For the final round of model refinement, we performed global realspace refinement with standard geometry restraints as well as rotamer, Ramachandran plot, Cbeta, noncrystallographic symmetry, and secondary structure restraints, coupled to reciprocalspace refinement of the Bfactors. Refinement was performed including all side chains and with both cholesterol molecules. Refinement statistics of that model are given in Extended Data Table 1 .
For validation of the refinement, random shifts (up to 0.3 Å) were introduced into the coordinates of the final refined model, followed by refinement with phenix. real_space_refine (using the same parameters as described before) against the first unfiltered halfmap (halfmap 1). The small 'gap' between the FSC curve of the model with random displacements refined against halfmap 1 versus halfmap 1 and the FSC curve of the same model versus halfmap 2 (against which it was not refined) indicated no overrefinement took place (Extended Data Fig. 2g ) 71, 72 . Orientation determination of yellow fluorescent protein-3C-ABCG2 in proteoliposomes. ABCG2 was Nterminally tagged with yellow fluorescent protein (YFP) and 3C protease (YFP-3C-ABCG2), and was expressed, purified, and reconstituted into liposomes as described above. The sample was divided into two (disrupted and nondisrupted). Triton X100 (1% v/v) was added to the 'disrupted' sample while the equivalent volume of transport buffer was added to the 'nondisrupted' sample, and both were incubated for 30 min at room temperature. 3C was added to both samples to cleave the YFP and the samples were centrifuged at 100,000g. Supernatants were collected and analysed by reducing SDS-PAGE ingel fluorescence using ImageJ. Pull-down assays of human and rat ABCG2 using 5D3-Fab. Expression and solubilization of YFPtagged human ABCG2 and of YFPtagged rat ABCG2 was performed as described above but without kifunensine treatment. After ultracen trifugation, the supernatants were incubated with 5D3monoclonal antibody coupled sepharose resin. The resin was washed extensively with purification buffer and analysed by reducing SDS-PAGE ingel fluorescence. Expression, purification, crystallization, and structure determination of the 5D3-Fab. The 5D3 hybridoma cells, producing the 5D3 monoclonal antibody, were obtained from B. Sorrentino 16 and cultured in WHEATON CELLine Bioreactors according to the manufacturer's protocol. 5D3Fab was purified from the superna tant as described in the Fab Preparation Kit protocol (Thermo Fisher Scientific). The purity and yield of 5D3Fab were evaluated by reducing and nonreducing SDS-PAGE, and the purified protein was crystallized in 100 mM Tris pH 8.5 and 16% PEG 6000 at 20 °C. A single 5D3Fab crystal was mounted at 100 K on the goniometer of beamline PXI at the Swiss Light Source and a complete data set was collected to a maximum resolution of 1.5 Å (Extended Data Table 2 ). The 5D3Fab Xray structure was determined by molecular replacement in Phaser 73 using the Fab of PDB accession number 4CAD as the search model 74 . Iterative model building was performed in Coot 75 and the Xray structure was refined in PHENIX 70 .
Figure preparation.
Figures were prepared using the programs PyMOL (The PyMOL Molecular Graphics System, DeLano Scientific) and Chimera 76 . Data availability. Atomic coordinates of the ABCG2-5D3(Fab) model after truncating the side chains of the NBD and of the 5D3Fab constant domain to alanine and removing the two cholesterol molecules have been deposited in the PDB under accession number 5NJ3. The de novo built structure of the ABCG2 TMD in complex with 5D3Fab variable domain was separately deposited in the Protein Data Bank (PDB) under accession number 5NJG. Atomic coordinates of the Xray structure of 5D3Fab have been deposited in the PDB under acces sion number 5NIV, and the threedimensional cryoEM density post processed, masked map has been deposited in the Electron Microscopy Data Bank (EMDB) under accession number EMD3654. All other data are available from the corre sponding authors upon reasonable request.
